TAM-derived IL6 induces CRC chemotherapy resistance by activating the IL6R/STAT3/miR-204-5p axis, which can be reversed by miR-204-5P overexpression or IL6 blockers [326]. Here, STAT3 is linked to colorectal carcinoma.